of

**RPMS 102** 



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OM8 control number Substitute for form 1449A/PTO Complete if Known 09/101,413 Application Number INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheet August 7, 1998 Filing Date Hans Josef Stauss First Named Inventor 1643 Group Art Unit

Sheet	1	of	` · · · · ·	S S S S S S S S S S S S S S S S S S S		
				U.S. PATENT DOCU	MENTS	
Examiner Initials*	Cite No.¹	US Patent Docu	ment	Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		140111001	Code 2			
		1	known)		07-04-1989	
16		4,844,893	<u> </u>	Honsik, et al.	09-01-1987	
MTC		4,690,915		Rosenberg		
			L			

Examiner Name

Attorney Docket Number

		OTHER ART NON PATENT LITERATURE DOCUMENTS	T2	
xaminer's Initials*	No.1 item (book, magazine, journal, senal, symposium, detail, where published			
NU		DAHL, et al., "Normal Self Proteins as Targets for Tumour Specific Cytotoxic Lymphocytes (CTL)," 9th International Congress of Immunology, San Francisco, CA, USA 607 (1995).		
1111		DAHL, et al., "A synthetic peptide derived from the tumor-associated protein mdm2 can stimulate autoreactive, high avidity cytotoxic T lymphocytes that recognize naturally processed protein," <i>J Immunol</i> 157(1):239-46 (1996).		
		HILL, et al., "Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised," J Exp Med 181(6):2221-8		
-		(1995). HSU, et al., "Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells," Nat Med 2(1):52-8 (1996).		
		INOUE, et al., "Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels," <i>Blood</i> 88(6):2267-78 (1996).		
_		JEROME, et al., "Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA," J Immunol		
	-	151(3):1654-62 (1993).  KAWAKAMI, et al., "Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas," <i>J Immunol</i> 148(2):638-43 (1992).		

<u> </u>		
Examine	Considered	2010
Signature	VII. II WOO	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.



er the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information	unless it contains a valid OMB control number	
Substitute for form 1449A/PTO	O I P Complete i	if Known
STATEMENT BY APPLICANT	Application Number  MAY 1 7 1999	09/101,413
(use as many sheets as necessary)	Filing Date RADEMARK	August 7, 1998 Hans Josef Stauss
	First Named Inventor	1643
	Group Art Unit	
of 3	Examiner Name Attorney Docket Number	RPMS 102

			of	3	Attorney Docket Number	REMO TOE
heet	2					
				OTHER ART	NON PATENT LITERATURE DOCUM	MENTS
		_				
xaminer'	s Cite		In	clude name of the autho	or (in CAPITAL LETTERS), title of the article hal, serial, symposium, catalog, etc.), date,	page(s), volume-issue number(s),
Initials*	No. 1	Į	iter	n (book, magazine, journ	publisher, cit and/or country where publi	shed
	Ļ	Į.			publisher, cit and/or country	tively immunised marrow donor," Lancet
		KWAK, et	al., "T	ransfer of myeloma	idiotype-specific initiality from all as	1
Ma		345(8956	1:1016	-20 (1995).		
Min		0 10,000				Cham, 46: 3433-3436 (1981).
		III et al	"Impr	oved Synthesis of 4-	Alkoxybenzyl Alcohol Resin," J. Org.	Chem. 40. 5450 0 100 (100 1)
- 1	ł	LO, et al.,	шири	0100 0 7		ļ
- 1	i					2012 Suppl 31:32-3
		1		to of T cell immunot	herapy for cancer by peptide vaccina	tion," Semin Hematol 30(3 Suppl 3):32-3
	1		rrospec	SES OF 1-CON INTIMUDIO		
i	1	(1993).				
1	1	l		T VACOUR	a' tumor gane (wt1) transcripts and t	the WT1 nuclear protein in the majority of
		MENNSE	N, et al.	, "Presence of Wilm	101.1060 7 (1995)	he WT1 nuclear protein in the majority of
1	i	buman ac	ute leu	kemias," <i>Leukemia</i> 9	(0):1000-7 (1350):	
1	i	1				using autologous dendritic cells pulsed with Prostate 29(6):371-80 (1996).
-		MURPHY	et al.,	"Phase I clinical tria	al: T-cell therapy for prostate cancer of the control of the contr	Prostate 29(6):371-80 (1996).
	1	IUI Λ-ΔΩ2	Ω1-sne	cific peptides from Pr	rostate-specific momerane	
	Ì	11124 7102	• · -			ytes recognize the same HER2/neu-derived
		DEODI ES	et al	"Breast and ovariar	cancer-specific cytotoxic T lymphoc	ytes recognize the same training
1	İ	PEUPLES	, GL 01.,	latl Acad Sci U S A 9	)2(2):432-6 (1995).	<b>1</b>
1	1	peptide,	PIUC N	all Acad Sol S S 7		from human peripheral
-1		<del></del>		"Industion of per	otide-specific primary cytotoxic T lym	phocyte responses from human peripheral
	1	PLEBANS	KI, et	al., induction of per	/1995)	
	1	blood," E	ur J Im	munol 25(6):1783-7	(1330).	
1 1	ŀ	l			1 Wilms' tumor gene by normal an	d malignant human melanocytes," Int J
<b>-</b>		RODECK	, et al.,	"Expression of the	W() Willia tallor gold by Herman	
1 1	1	Cancer	9/11-7/	a(1)·78-82 (1994).		Į.
1					f the auto/monkaryo	exterrelated transcription factors GATA-1 and
<u> </u>	<del></del>	SHIMAN	OTO, e	et al., "The expression	on pattern of erythrocyte/megakaryoc	yte-related transcription factors GATA-1 and and is associated with outcome of acute
	<b>!</b>	the ctem	cell le	ukemia dene correlati	62 Milli Helligrobologie	and is associated with outcome of acute
1		myoloid	laukem	ia," Blood 86(8):317	3-80 (1995).	e release in acute leukemia." Blood
	<del>( / </del> -	TANAL	et al	"Increased express	3-80 (1995). ion of the Wilms tumor gene (WT1) a	t relapse in acute leukering, 2,000
	١	IAWAN	, <del>U</del> L di.,	/1996)		
	- 1	88(11):4	+230-0	(1000).		
1	- 1					

1	_		
<u> </u>			
		Date	1-12-7000
Examiner's	$\sim$ $\sim$ $\sim$ $\sim$ $\sim$	Considered	1-10-00
Signature	100 1. 000		

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RPMS 102 20001/6

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box  $\rightarrow$ 

		0	I	P	E	\
	(-	MAY	1	7	1999	000
respond to a collection of information	unless it coutsits	a valid Ol	MB c	ontr	ol number	<u>ک</u>
		•				ҳ

PTO/SB/08A (10-96 Approved for use through 10/31/99. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

S	ubstit	ute for	form 14	49A/PTO	TRADEMARKOT C	omplete if Known	
				N DISCLOSURE BY APPLICANT	Application Number	09/101,413	
		(use a	s many s	heets as necessary)	Filing Date	August 7, 1998	
					First Named Inventor	Hans Josef Stauss	
					Group Art Unit	1643	
					Examiner Name		
Sheet		3	of	3	Attorney Docket Number	RPMS 102	
				OTHER ART	NON PATENT LITERATURE DOCUM	MENTS	T2
Examiner's	Cite		-	Include name of the author (	in CAPITAL LETTERS), title of the article	(when appropriate), title of the	'
Initials*	No.1			ľ	serial, symposium, catalog, etc.), date, publisher, cit and/or country where publisher.	shed	
MY	/		et al., "I 515-21	Molecular mechanisms pos	ssibly affecting WT1 function in hu	man ovarian tumors," Int J Cancer	
		<del> </del>					

	Date	117700
xaminer's M	Considered	1 1/1/2/100
ignature /// \	Considered	( 10
<u> </u>		
•		war and the state of the same and the same and the state of the same and the same a

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.